456 related articles for article (PubMed ID: 25004168)
21. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
[TBL] [Abstract][Full Text] [Related]
22. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.
Wedzicha JA; Singh D; Vestbo J; Paggiaro PL; Jones PW; Bonnet-Gonod F; Cohuet G; Corradi M; Vezzoli S; Petruzzelli S; Agusti A;
Respir Med; 2014 Aug; 108(8):1153-62. PubMed ID: 24953015
[TBL] [Abstract][Full Text] [Related]
23. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
24. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD.
Corda L; Bertella E; La Piana GE; Boni E; Redolfi S; Tantucci C
Respiration; 2008; 76(1):61-8. PubMed ID: 18319586
[TBL] [Abstract][Full Text] [Related]
25. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
26. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
27. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
[TBL] [Abstract][Full Text] [Related]
28. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
Mahler DA; Waterman LA; Ward J; Gifford AH
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):103-9. PubMed ID: 23745526
[TBL] [Abstract][Full Text] [Related]
31. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.
Hanania NA; Sethi S; Koltun A; Ward JK; Spanton J; Ng D
Int J Chron Obstruct Pulmon Dis; 2019; 14():117-127. PubMed ID: 30643398
[TBL] [Abstract][Full Text] [Related]
33. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
Barnes N; van Noord JA; Brindicci C; Lindemann L; Varoli G; Perpiña M; Guastalla D; Casula D; Patel S; Chanez P;
Pulm Pharmacol Ther; 2013 Oct; 26(5):555-61. PubMed ID: 23524015
[TBL] [Abstract][Full Text] [Related]
34. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
[No Abstract] [Full Text] [Related]
35. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
Voorham J; Baldi S; Santoro L; Kerkhof M; Contoli M; Fabbri LM; Kerstjens HAM; Luis López-Campos J; Roche N; Singh D; Vogelmeier CF; Price DB
Int J Chron Obstruct Pulmon Dis; 2020; 15():2739-2750. PubMed ID: 33149571
[TBL] [Abstract][Full Text] [Related]
36. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
37. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma.
Price D; Thomas M; Haughney J; Lewis RA; Burden A; von Ziegenweidt J; Chisholm A; Hillyer EV; Corrigan CJ
Respir Med; 2013 Jul; 107(7):987-1000. PubMed ID: 23643486
[TBL] [Abstract][Full Text] [Related]
38. Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD.
Borel B; Wilkinson-Maitland CA; Hamilton A; Bourbeau J; Perrault H; Jensen D; Maltais F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2991-3000. PubMed ID: 27942208
[TBL] [Abstract][Full Text] [Related]
39. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.
Singh D; Nicolini G; Bindi E; Corradi M; Guastalla D; Kampschulte J; Pierzchała W; Sayiner A; Szilasi M; Terzano C; Vestbo J;
BMC Pulm Med; 2014 Mar; 14():43. PubMed ID: 24621109
[TBL] [Abstract][Full Text] [Related]
40. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
